Report Detail

Other Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, Status and Forecast 2021-2027

  • RnM4284406
  • |
  • 04 February, 2021
  • |
  • Global
  • |
  • 93 Pages
  • |
  • QYResearch
  • |
  • Other

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Transthyretin Stabilizers
    • 1.2.3 Nonsteroidal Anti-inflammatory Drugs (NSAID)
    • 1.2.4 RNAi Therapy
    • 1.2.5 Others
  • 1.3 Market by Application
    • 1.3.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Hereditary Transthyretin Amyloidosis (hATTR)
    • 1.3.3 Wild Type Transthyretin Amyloidosis (wtATTR)
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Perspective (2016-2027)
  • 2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Growth Trends by Regions
    • 2.2.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Share by Regions (2016-2021)
    • 2.2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Regions (2022-2027)
  • 2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industry Dynamic
    • 2.3.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Trends
    • 2.3.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers
    • 2.3.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges
    • 2.3.4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue
    • 3.1.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue (2016-2021)
    • 3.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Players (2016-2021)
  • 3.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue
  • 3.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio
    • 3.4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2020
  • 3.5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Key Players Head office and Area Served
  • 3.6 Key Players Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Solution and Service
  • 3.7 Date of Enter into Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Type

  • 4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Type (2016-2021)
  • 4.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Type (2022-2027)

5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Application

  • 5.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Application (2016-2021)
  • 5.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
  • 6.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
    • 6.2.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
    • 6.2.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
    • 6.2.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
  • 6.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
    • 6.3.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
    • 6.3.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
    • 6.3.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
  • 6.4 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
    • 6.4.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
    • 6.4.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.3 Canada

7 Europe

  • 7.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
  • 7.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
    • 7.2.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
    • 7.2.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
    • 7.2.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
  • 7.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
    • 7.3.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
    • 7.3.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
    • 7.3.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
  • 7.4 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
    • 7.4.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
    • 7.4.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
  • 8.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
    • 8.2.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
    • 8.3.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
    • 8.4.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
  • 9.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
    • 9.2.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
    • 9.2.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
    • 9.2.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
  • 9.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
    • 9.3.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
    • 9.3.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
    • 9.3.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
  • 9.4 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
    • 9.4.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
    • 9.4.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
  • 10.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
    • 10.2.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
    • 10.3.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
    • 10.4.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Pfizer Inc
    • 11.1.1 Pfizer Inc Company Details
    • 11.1.2 Pfizer Inc Business Overview
    • 11.1.3 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
    • 11.1.4 Pfizer Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    • 11.1.5 Pfizer Inc Recent Development
  • 11.2 GlaxoSmithKline Plc
    • 11.2.1 GlaxoSmithKline Plc Company Details
    • 11.2.2 GlaxoSmithKline Plc Business Overview
    • 11.2.3 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
    • 11.2.4 GlaxoSmithKline Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    • 11.2.5 GlaxoSmithKline Plc Recent Development
  • 11.3 Eidos Therapeutics
    • 11.3.1 Eidos Therapeutics Company Details
    • 11.3.2 Eidos Therapeutics Business Overview
    • 11.3.3 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
    • 11.3.4 Eidos Therapeutics Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    • 11.3.5 Eidos Therapeutics Recent Development
  • 11.4 Ionis Pharmaceuticals, Inc
    • 11.4.1 Ionis Pharmaceuticals, Inc Company Details
    • 11.4.2 Ionis Pharmaceuticals, Inc Business Overview
    • 11.4.3 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
    • 11.4.4 Ionis Pharmaceuticals, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    • 11.4.5 Ionis Pharmaceuticals, Inc Recent Development
  • 11.5 Alnylam Pharmaceuticals
    • 11.5.1 Alnylam Pharmaceuticals Company Details
    • 11.5.2 Alnylam Pharmaceuticals Business Overview
    • 11.5.3 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
    • 11.5.4 Alnylam Pharmaceuticals Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    • 11.5.5 Alnylam Pharmaceuticals Recent Development
  • 11.6 Prothena Corporation Plc
    • 11.6.1 Prothena Corporation Plc Company Details
    • 11.6.2 Prothena Corporation Plc Business Overview
    • 11.6.3 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
    • 11.6.4 Prothena Corporation Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    • 11.6.5 Prothena Corporation Plc Recent Development
  • 11.7 Intellia Therapeutics, Inc
    • 11.7.1 Intellia Therapeutics, Inc Company Details
    • 11.7.2 Intellia Therapeutics, Inc Business Overview
    • 11.7.3 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
    • 11.7.4 Intellia Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    • 11.7.5 Intellia Therapeutics, Inc Recent Development
  • 11.8 Corino Therapeutics, Inc
    • 11.8.1 Corino Therapeutics, Inc Company Details
    • 11.8.2 Corino Therapeutics, Inc Business Overview
    • 11.8.3 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
    • 11.8.4 Corino Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    • 11.8.5 Corino Therapeutics, Inc Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

    Segment by Type
    Transthyretin Stabilizers
    Nonsteroidal Anti-inflammatory Drugs (NSAID)
    RNAi Therapy
    Others

    Segment by Application
    Hereditary Transthyretin Amyloidosis (hATTR)
    Wild Type Transthyretin Amyloidosis (wtATTR)

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia
    Latin America
    Mexico
    Brazil
    Rest of Latin America
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of MEA

    By Company
    Pfizer Inc
    GlaxoSmithKline Plc
    Eidos Therapeutics
    Ionis Pharmaceuticals, Inc
    Alnylam Pharmaceuticals
    Prothena Corporation Plc
    Intellia Therapeutics, Inc
    Corino Therapeutics, Inc
    Ionis Pharmaceuticals, Inc


    Summary:
    Get latest Market Research Reports on Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment. Industry analysis & Market Report on Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment is a syndicated market report, published as Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, Status and Forecast 2021-2027. It is complete Research Study and Industry Analysis of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,900.00
    $5,850.00
    $7,800.00
    2,797.31
    4,195.97
    5,594.63
    3,239.80
    4,859.69
    6,479.59
    419,647.80
    629,471.70
    839,295.60
    284,179.35
    426,269.03
    568,358.70
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report